Correct Answer

B — Nitroglycerin sublingual tablet

Rationale

Nitroglycerin sublingual tablet is the standard formulation classified for acute angina management. The sublingual route allows direct absorption through the oral mucosa into the systemic venous circulation, bypassing hepatic first-pass metabolism and producing rapid onset of action within one to three minutes. Oral isosorbide mononitrate is a long-acting nitrate used for angina prophylaxis. Transdermal nitroglycerin provides sustained release for prophylaxis and is not used for acute episodes. Intravenous nitroglycerin is used in hospital settings for unstable angina and acute coronary syndromes, not for outpatient acute management.

Correct Answer

D — Lithium

Rationale

Lithium is classified as an oral-only agent; no parenteral formulation is approved for clinical use. It is administered exclusively as oral tablets or capsules. Phenytoin, valproic acid, and lorazepam are each available in both oral and intravenous formulations, allowing parenteral administration when oral access is not possible.

Correct Answer

A — Subcutaneous

Rationale

Insulin is classified as a subcutaneous agent for outpatient diabetes management. Subcutaneous injection into adipose tissue provides predictable absorption kinetics appropriate for blood glucose control. Oral administration is not used because insulin is a peptide that is degraded by gastrointestinal proteases before reaching systemic circulation. Sublingual and intramuscular are not standard routes for insulin in outpatient practice.

Correct Answer

C — Fentanyl

Rationale

Fentanyl is the opioid classified as a transdermal patch formulation for chronic pain management. Its high lipophilicity allows effective absorption through intact skin, providing sustained systemic delivery over 72 hours per patch. Morphine, oxycodone, and hydromorphone are available in oral and parenteral formulations but are not classified as transdermal patch agents.

Correct Answer

B — Intravenous and subcutaneous only

Rationale

Unfractionated heparin is classified as an agent given by intravenous infusion or subcutaneous injection only. It is not absorbed orally because it is a large, highly charged polysaccharide that cannot cross the gastrointestinal mucosa. Intramuscular injection is avoided because it carries a risk of hematoma formation at the injection site.

Correct Answer

D — Tacrolimus

Rationale

Tacrolimus is classified as an oral immunosuppressant that undergoes extensive first-pass metabolism, primarily by cytochrome P450 3A4 in the intestinal wall and liver. This results in low and highly variable oral bioavailability, which is a defining pharmacokinetic characteristic used to classify this drug and explains the need for therapeutic drug monitoring. Azathioprine, mycophenolate mofetil, and sirolimus do not share this same degree of cytochrome P450 3A4-mediated first-pass variability.

Correct Answer

A — The acidic gastric environment keeps more drug in the un-ionized form, which crosses membranes more readily

Rationale

Weak acids are less ionized in acidic environments. When gastric pH is well below the drug pKa, the Henderson-Hasselbalch relationship predicts that the majority of the drug exists in the un-ionized form. Un-ionized drug is lipophilic and can passively diffuse across the lipid bilayer of the gastric mucosa. In the more alkaline small intestine, more of the weak acid is ionized, making it less membrane-permeant. Absorption from the stomach is therefore favored for weak acid drugs despite the stomach having a much smaller absorptive surface area than the small intestine.

Correct Answer

C — A large fraction of oral morphine is metabolized by the liver before reaching systemic circulation

Rationale

Morphine is a high-extraction drug subject to extensive hepatic first-pass metabolism. When absorbed from the gastrointestinal tract, morphine passes through the portal circulation and is substantially metabolized by the liver before reaching systemic circulation. This first-pass effect reduces oral bioavailability to approximately 25 to 35 percent, meaning that a much larger oral dose is needed to deliver the same amount of drug to the systemic circulation as a given intravenous dose. Intravenous administration bypasses the liver entirely on the first pass, delivering the full dose to the systemic circulation.

Correct Answer

B — The fraction of an administered dose that reaches the systemic circulation in unchanged form

Rationale

Bioavailability is defined as the fraction of an administered dose that reaches the systemic circulation in unchanged, pharmacologically active form. For an intravenous dose, bioavailability is by definition 100 percent. For oral and other non-intravenous routes, bioavailability is reduced by incomplete absorption and first-pass metabolism. The rate of reaching peak concentration describes Tmax, not bioavailability. The volume of plasma cleared per unit time defines clearance. The maximum plasma concentration describes Cmax.

Correct Answer

D — Drug absorbed sublingually drains into the systemic venous circulation, bypassing the portal circulation and hepatic metabolism

Rationale

The venous drainage of the sublingual mucosa flows into the superior vena cava rather than the portal vein, so drug absorbed sublingually enters the systemic circulation directly without first passing through the liver. Nitroglycerin given orally undergoes nearly complete hepatic first-pass metabolism, leaving very little unchanged drug to reach systemic circulation. The sublingual route bypasses this first-pass effect entirely, explaining the far higher bioavailability. The sublingual mucosa does not have high concentrations of drug-metabolizing enzymes, and solubility or gastric emptying are not relevant to this comparison.

Correct Answer

A — Grapefruit juice inhibits cytochrome P450 3A4 in the intestinal wall, reducing first-pass metabolism of simvastatin

Rationale

Furanocoumarins in grapefruit juice irreversibly inhibit cytochrome P450 3A4 in the enterocytes of the small intestinal wall. Simvastatin is a cytochrome P450 3A4 substrate that normally undergoes significant first-pass metabolism in the intestinal mucosa and liver. When intestinal cytochrome P450 3A4 is inhibited, less simvastatin is metabolized before reaching systemic circulation, substantially increasing bioavailability and plasma concentrations. This interaction is clinically important because elevated simvastatin concentrations increase the risk of myopathy and rhabdomyolysis. Grapefruit juice does not induce cytochrome P450 3A4 and does not affect gastric emptying or drug solubility in a clinically relevant way.

Correct Answer

C — To sustain therapeutic plasma concentrations over a longer interval, reducing dosing frequency

Rationale

Extended-release formulations are designed to release drug gradually over an extended period, sustaining plasma concentrations within the therapeutic range for a longer interval than the immediate-release form. This allows less frequent dosing — often once or twice daily instead of three or four times daily — which improves adherence and reduces peak-trough fluctuation. Extended-release formulations do not increase the maximum plasma concentration; they typically produce a lower, broader peak. They slow, rather than accelerate, absorption. Total bioavailability may be similar to or slightly lower than the immediate-release form, not higher.

Correct Answer

B — The acidic gastric environment ionizes most of the weak base, trapping it in the aqueous luminal contents and reducing membrane permeation

Rationale

Weak bases become ionized in acidic environments. When gastric pH is well below the drug pKa of 8.0, the Henderson-Hasselbalch relationship predicts that the vast majority of the drug is in the ionized, positively charged form. Ionized drug is hydrophilic and cannot readily cross the lipid bilayer of the gastric mucosa, so it remains trapped in the acidic gastric fluid. In the more alkaline small intestine, where pH approaches and partially exceeds the pKa, a greater fraction of the drug is un-ionized and membrane-permeant, allowing effective absorption. This ion-trapping principle is why most weak base drugs are predominantly absorbed from the small intestine rather than the stomach.

Correct Answer

D — Enalaprilat is poorly absorbed orally because of its hydrophilic nature, while enalapril has better oral bioavailability

Rationale

Enalaprilat, the active diacid form of the angiotensin converting enzyme inhibitor, is highly polar and hydrophilic, which severely limits its absorption across the lipophilic gastrointestinal mucosa. Oral bioavailability of enalaprilat is only about 10 percent. Enalapril was designed as an ethyl ester prodrug that masks this polarity, increasing lipophilicity and allowing adequate oral absorption with bioavailability of approximately 60 percent. After absorption, hepatic esterases cleave the ester bond to release the active enalaprilat. This prodrug strategy solved the oral bioavailability problem while preserving the pharmacodynamic activity of the active metabolite.

Correct Answer

C — Grapefruit juice inhibits cytochrome P450 3A4 in the intestinal wall, increasing cyclosporine bioavailability and raising plasma concentrations to toxic levels

Rationale

Furanocoumarins in grapefruit juice irreversibly inhibit cytochrome P450 3A4 in intestinal enterocytes. Cyclosporine is a cytochrome P450 3A4 substrate that normally undergoes significant first-pass metabolism in the gut wall. When this metabolism is blocked, a greater fraction of the oral dose reaches systemic circulation, raising cyclosporine plasma concentrations. Elevated cyclosporine levels cause the classic toxicity triad of nephrotoxicity (rising creatinine), neurotoxicity (tremor), and hypertension. Grapefruit juice inhibits, rather than induces, cytochrome P450 3A4, and it does not form complexes with drugs or displace protein binding.

Correct Answer

A — Cirrhosis reduces hepatic first-pass metabolism of morphine, increasing the fraction that reaches systemic circulation

Rationale

Morphine is a high-extraction drug that normally undergoes extensive hepatic first-pass metabolism, with only about 25 to 35 percent of an oral dose reaching systemic circulation in patients with normal liver function. In cirrhosis, hepatocyte loss and portosystemic shunting dramatically reduce the liver's capacity for first-pass metabolism. A much greater fraction of each oral dose therefore bypasses metabolism and reaches the systemic circulation, producing plasma concentrations far higher than intended at standard doses. The result is opioid toxicity — sedation and respiratory depression — at doses that would be safe in a patient without liver disease. Oral dosing of high-extraction drugs requires substantial dose reduction in significant liver disease.

Correct Answer

B — Crushing destroys the extended-release matrix, releasing the full 60 mg dose immediately and causing acute toxicity

Rationale

Extended-release formulations use a matrix, membrane, or osmotic system to control the rate of drug release over many hours. Crushing the tablet physically destroys this delivery system, converting the extended-release preparation into an immediate-release form. The full 60 mg dose — intended for gradual release over 24 hours — is instead absorbed rapidly, producing plasma concentrations far exceeding the therapeutic range. The resulting acute calcium channel blockade causes severe vasodilation, hypotension, flushing, and reflex tachycardia. This is the mechanism of dose-dumping, a serious hazard when extended-release tablets are crushed, chewed, or broken.

Correct Answer

D — Sublingual absorption bypasses hepatic first-pass metabolism, allowing rapid entry of intact nitroglycerin into the systemic circulation

Rationale

The sublingual mucosa drains directly into the systemic venous circulation, bypassing the portal vein and the liver. Nitroglycerin absorbed under the tongue enters the bloodstream as intact drug without undergoing hepatic first-pass metabolism, producing systemic vasodilation within one to three minutes. If swallowed, nitroglycerin undergoes nearly complete first-pass metabolism in the liver, leaving insufficient intact drug to produce a therapeutic effect. The sublingual and oral forms of nitroglycerin are the same drug — the route of administration, not the formulation chemistry, determines the clinical outcome.